<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Serological profiling of the EBV immune response in Chronic Fatigue Syndrome using a peptide microarray</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-06-12">June 12, 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Madlen</forename><surname>Loebel</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Medical Immunology</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<addrLine>Campus Virchow</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maren</forename><surname>Eckey</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution">JPT Peptide Technologies GmbH</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Franziska</forename><surname>Sotzny</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Medical Immunology</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<addrLine>Campus Virchow</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elisabeth</forename><surname>Hahn</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Medical Immunology</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<addrLine>Campus Virchow</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sandra</forename><surname>Bauer</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Medical Immunology</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<addrLine>Campus Virchow</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Patricia</forename><surname>Grabowski</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Medical Immunology</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<addrLine>Campus Virchow</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Johannes</forename><surname>Zerweck</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution">JPT Peptide Technologies GmbH</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pavlo</forename><surname>Holenya</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution">JPT Peptide Technologies GmbH</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Leif</forename><forename type="middle">G</forename><surname>Hanitsch</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Medical Immunology</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<addrLine>Campus Virchow</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kirsten</forename><surname>Wittke</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Medical Immunology</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<addrLine>Campus Virchow</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Borchmann</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department I of Internal Medicine</orgName>
								<orgName type="laboratory">German Hodgkin Study Group (GHSG)</orgName>
								<orgName type="institution">University Hospital of Cologne</orgName>
								<address>
									<settlement>Cologne, Cologne</settlement>
									<country>Germany, Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jens-Ulrich</forename><surname>Ru</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">German Fatigue Society e.V. (DFaG)</orgName>
								<address>
									<settlement>Cologne, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Falk</forename><surname>Hiepe</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Rheumatology and Clinical Immunology</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Klemens</forename><surname>Ruprecht</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Neurology and Clinical and Experimental Multiple Sclerosis Research Center</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Uta</forename><surname>Behrends</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution" key="instit1">Children&apos;s Hospital Schwabing</orgName>
								<orgName type="institution" key="instit2">Technische Universita ¨t Mu ¨nchen (TUM)</orgName>
								<address>
									<settlement>Munich, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">Department of Gene Vectors</orgName>
								<orgName type="institution">Helmholtz Center Munich (HMGU)</orgName>
								<address>
									<settlement>Munich, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">German Center for Infection Research (DZIF)</orgName>
								<orgName type="department" key="dep2">Center for Regenerative Therapies (BCRT)</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<addrLine>Partner Site Munich, 10 Berlin-Brandenburg</addrLine>
									<settlement>Munich, Germany, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Carola</forename><surname>Meindl</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution" key="instit1">Children&apos;s Hospital Schwabing</orgName>
								<orgName type="institution" key="instit2">Technische Universita ¨t Mu ¨nchen (TUM)</orgName>
								<address>
									<settlement>Munich, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">Department of Gene Vectors</orgName>
								<orgName type="institution">Helmholtz Center Munich (HMGU)</orgName>
								<address>
									<settlement>Munich, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hans-Dieter</forename><surname>Volk</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Medical Immunology</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<addrLine>Campus Virchow</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ulf</forename><surname>Reimer</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution">JPT Peptide Technologies GmbH</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Carmen</forename><surname>Scheibenbogen</surname></persName>
							<email>carmen.scheibenbogen@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">Institute of Medical Immunology</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<addrLine>Campus Virchow</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<orgName type="institution" key="instit1">University of North Carolina at Chapel Hill</orgName>
								<orgName type="institution" key="instit2">UNITED STATES</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">Serological profiling of the EBV immune response in Chronic Fatigue Syndrome using a peptide microarray</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-06-12">June 12, 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">510506968515AE800D161F5B1DFAD632</idno>
					<idno type="DOI">10.1371/journal.pone.0179124</idno>
					<note type="submission">Received: June 22, 2016 Accepted: May 24, 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:51+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background</head><p><s>Epstein-Barr-Virus (EBV) plays an important role as trigger or cofactor for various autoimmune diseases.</s><s>In a subset of patients with Chronic Fatigue Syndrome (CFS) disease starts with infectious mononucleosis as late primary EBV-infection, whereby altered levels of EBVspecific antibodies can be observed in another subset of patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>We performed a comprehensive mapping of the IgG response against EBV comparing 50 healthy controls with 92 CFS patients using a microarray platform.</s><s>Patients with multiple sclerosis (MS), systemic lupus erythematosus (SLE) and cancer-related fatigue served as controls.</s><s>3054 overlapping peptides were synthesised as 15-mers from 14 different EBV proteins.</s><s>Array data was validated by ELISA for selected peptides.</s><s>Prevalence of EBV serotypes was determined by qPCR from throat washing samples.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>EBV type 1 infections were found in patients and controls.</s><s>EBV seroarray profiles between healthy controls and CFS were less divergent than that observed for MS or SLE.</s><s>We found significantly enhanced IgG responses to several EBNA-6 peptides containing a repeat sequence in CFS patients compared to controls.</s><s>EBNA-6 peptide IgG responses correlated</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Epstein-Barr Virus (EBV) infection plays a critical role in various autoimmune diseases such as Multiple Sclerosis (MS), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA) or Sjo ¨gren's syndrome <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref>.</s><s>There is a link between infectious mononucleosis and an increased risk for MS and seroprevalence of EBV is close to 100% in MS <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref>.</s><s>Several studies show homologies of EBV sequences with human autoantigens such as myelin basic protein for MS <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b10">11]</ref> and smith antigen for SLE <ref type="bibr" target="#b11">[12]</ref>.</s></p><p><s>With an estimated prevalence of 0.3% CFS affects more people than MS and SLE <ref type="bibr" target="#b12">[13]</ref>.</s><s>CFS is a multisystem disorder characterized by severe fatigue with the hallmark symptom of exertion intolerance and post-exertional delay to recover, and cognitive dysfunctions <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b14">15]</ref>.</s><s>CFS is probably a heterogeneous disease, but currently no diagnostic biomarkers are available <ref type="bibr">[16]</ref><ref type="bibr" target="#b15">[17]</ref><ref type="bibr" target="#b16">[18]</ref><ref type="bibr" target="#b17">[19]</ref><ref type="bibr" target="#b18">[20]</ref>. Some studies describe immune dysregulation and activation in CFS patients <ref type="bibr" target="#b19">[21]</ref><ref type="bibr" target="#b20">[22]</ref><ref type="bibr" target="#b21">[23]</ref>.</s><s>Numerous studies have tried to find evidence for an association of CFS with EBV.</s><s>In a subset of patients, CFS begins with infectious mononucleosis and evidence for a potential role of EBV in CFS comes from many studies.</s><s>In 1984 DuBois first described patients with the mononucleosis syndrome suffering from long-lasting fatigue and serological evidence of EBV reactivation <ref type="bibr" target="#b22">[24]</ref> followed by a number of studies describing patients with CFS with serological evidence of chronic active EBV infection <ref type="bibr" target="#b23">[25]</ref>.</s><s>A first placebo-controlled trial with acyclovir in CFS patients with serological active EBV infection performed by <ref type="bibr">Straus et al.</ref> showed no efficacy <ref type="bibr" target="#b24">[26]</ref> while trials with valacyclovir and valganciclovir showed moderate improvement in some patients <ref type="bibr" target="#b25">[27,</ref><ref type="bibr" target="#b26">28]</ref>.</s><s>Enhanced EBV-specific antibodies against VCA, early antigen and EBV DNAse as well as persistent IgM antibodies were described in numerous studies <ref type="bibr" target="#b27">[29]</ref><ref type="bibr" target="#b28">[30]</ref><ref type="bibr" target="#b29">[31]</ref><ref type="bibr" target="#b30">[32]</ref><ref type="bibr" target="#b31">[33]</ref><ref type="bibr" target="#b32">[34]</ref><ref type="bibr" target="#b33">[35]</ref><ref type="bibr" target="#b34">[36]</ref><ref type="bibr" target="#b35">[37]</ref> but findings were not consistent <ref type="bibr" target="#b36">[38]</ref><ref type="bibr" target="#b37">[39]</ref><ref type="bibr" target="#b38">[40]</ref>.</s></p><p><s>In a previous study, we found an elevated IgM response against the late VCA antigen but a lack of antibodies and memory B cells against EBNA-1 in another subset of EBV-positive CFS patients <ref type="bibr" target="#b39">[41]</ref>.</s><s>A diminished EBNA-1 IgG production was also reported in severe infectious mononucleosis and chronic active EBV infection <ref type="bibr" target="#b40">[42]</ref><ref type="bibr" target="#b41">[43]</ref><ref type="bibr" target="#b42">[44]</ref>.</s><s>In the present study, we therefore wanted to comprehensively analyse the antibody response against all major EBV proteins in a large cohort of CFS patients.</s><s>Further, we wanted to answer the question if reactivation of EBV occurs more frequently in CFS patients.</s></p><p><s>The EBV DNA genome is large and contains over 100 protein-coding genes <ref type="bibr" target="#b43">[45,</ref><ref type="bibr" target="#b44">46]</ref>.</s><s>In primary infection, EBV undergoes a short period of lytic replication in oral and nasal epithelium <ref type="bibr" target="#b45">[47]</ref><ref type="bibr" target="#b46">[48]</ref><ref type="bibr" target="#b47">[49]</ref>.</s><s>The orally transmitted EBV initially targets the mucosal epithelium and remains in a life-long latency in memory B cells <ref type="bibr" target="#b48">[50]</ref><ref type="bibr" target="#b49">[51]</ref><ref type="bibr" target="#b50">[52]</ref>.</s><s>In healthy subjects the EBV genome in B cells usually remains latent in the so-called latency phase 0 which maintains the genome in a quiescent state <ref type="bibr" target="#b51">[53]</ref><ref type="bibr" target="#b52">[54]</ref><ref type="bibr" target="#b53">[55]</ref><ref type="bibr" target="#b54">[56]</ref>.</s><s>This latency is controlled by NK-and T-cell responses.</s><s>Frequent replication the manuscript.</s><s>The specific roles of these authors are articulated in the 'author contributions' section.</s><s>The work was further supported by the Lost Voices Foundation e.V., and by a flex fund grant (07-905) from the German Center for Infection Research.</s><s>The authors ME, JZ, PH and UR are employed by a commercial company, JPT Peptide Technologies GmbH, and received support in the form of salaries.</s><s>JPT Peptide Technologies is not the funder of this study, but the recipient of the funding.</s><s>The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</s></p><p><s>occurs in epithelial cells of the pharynx.</s><s>Latency I is characterized by the expression of EBNA-1, latency II by latent membrane proteins (LMP)-1 and LMP-2, and latency III by EBNAs 2-6 <ref type="bibr" target="#b55">[57,</ref><ref type="bibr" target="#b56">58]</ref>.</s><s>During lytic reactivation the EBV immediate-early genes BZLF-1 and BRLF-1 are expressed.</s><s>These genes activate viral and cellular promoters that induce early, lytic and late viral gene expression and high amplification of the EBV genome <ref type="bibr" target="#b57">[59]</ref>.</s><s>There are EBV type-specific sequence variations in the EBNA genes that are used to characterize the two EBV major subtypes I or II <ref type="bibr" target="#b42">[44,</ref><ref type="bibr" target="#b58">60]</ref>.</s><s>The EBV types differ in their capacity to immortalize human B cells with type II EBV as the less efficient strain <ref type="bibr" target="#b59">[61]</ref>.</s></p><p><s>In this study, we performed a mapping of the IgG response against 14 EBV proteins by seroarray using overlapping peptide pools in CFS patients and healthy controls.</s><s>The HHV4 proteome consists of close to 90 proteins of which 8 have been functionally classified as capsid, 14 as membrane protein, 6 as nucleotide metabolism, 9 as latency, 5 as packaging, 7 as replication, 11 as transcription factors, transactivators or involved in signaling and 11 as tegument.</s><s>We selected one protein from each of these classes except for the latency class where we selected 5 and replication where three were selected.</s><s>Reactivity against these EBV proteins observed in CFS and healthy controls in our study was rather similar with an enhanced reactivity in CFS patients against a repeat region in EBNA-6.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study population</head><p><s>CFS patients were diagnosed at the Charite ´outpatient clinic for immunodeficiencies at the Institute of Medical Immunology at the Charite ´Universita ¨tsmedizin Berlin between 2011 and 2015.</s><s>Patients with MS were recruited at the Department of Neurology and patients with SLE at the Department of Rheumatology at the Charite ´Universita ¨tsmedizin Berlin <ref type="bibr" target="#b7">[8]</ref>.</s><s>Samples of 50 patients with cancer-related fatigue and 50 without fatigue following chemotherapy for Hodgkin's lymphoma were provided by the University Hospital of Cologne and the German Hodgkin Study Group (GHSG).</s><s>Diagnosis of CFS was based on Canadian Criteria <ref type="bibr" target="#b60">[62]</ref> and exclusion of other medical or neurological diseases which may cause fatigue.</s><s>Patients with systemic steroid or immunosuppressant therapy or a diagnosis of primary immunodeficiency were excluded from this study.</s><s>Around 80% of our patients had an onset of disease after acute infection.</s><s>Baseline demographic characteristics of the patients are shown in Table <ref type="table" target="#tab_0">1</ref>.</s><s>Controls were recruited from staff and did not suffer from fatigue.</s><s>However, neither clinical nor laboratory assessment was performed for controls.</s><s>The study was approved by the Ethics Committee of Charite ´Universita ¨tsmedizin Berlin in accordance with the 1964 Declaration of Helsinki and its later amendments and patients gave written informed consent.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Blood samples</head><p><s>Serum obtained from patients and healthy persons was stored in aliquots at -80˚C.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Peptide seroarray</head><p><s>IgG antibody responses to EBV peptides were determined by peptide microarrays as described before <ref type="bibr" target="#b7">[8]</ref>.</s><s>In brief, peptides were synthesized using SPOT synthesis and immobilized onto glass slides (JPT Peptide Technologies, Berlin).</s><s>Serum samples of healthy donor controls and patients were incubated for 1h and specific antibodies were detected by fluorescently labelled anti-IgG antibodies.</s><s>Signals were further processed for data analysis and statistical evaluation.</s><s>Data are reported as arbitrary fluorescence units.</s><s>Based on our previous study <ref type="bibr" target="#b7">[8]</ref> in which we had included two EBV seronegative healthy controls (EBV-VCA-and EBNA-IgG negative) revealing no or only little background reactivity, responder samples were defined as a signal intensity of &gt; 5,000 Units to exclude background signals.</s></p><p><s>The peptide library contained 3054 peptides covering the full-length EBV proteins BALF-2, BALF-5, BFRF-3 (VP26), BLLF-1, BLLF-3, BLRF-2, BMRF-1, BZLF-1, EBNA-1, EBNA-3, EBNA-4, EBNA-6, LMP-1 and LMP-2 of different EBV strains.</s><s>Additionally, a relatively conserved region from the N-terminus of VP1 (AA 42-75) of different Coxsackieviruses from the genus Enteroviridae which is described as highly reactive with patient sera was covered by 164 overlapping peptides <ref type="bibr" target="#b61">[63]</ref>.</s><s>The library was printed onto functionalized glass slides in triplicates.</s><s>The proteins were represented as peptides consisting of 15 amino acids (15-mer) which exhibited optimal overlap of 11 amino acids in most cases to cover the EBV sequence diversity including but not limited to strains of type I (B95.8) and type II (AG876) at minimum peptide numbers (S1 and S2 Files).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Multiwell assay</head><p><s>IgG antibody responses against a selection of 128 EBV peptides were determined as described elsewhere <ref type="bibr" target="#b62">[64]</ref>.</s><s>In brief, sera were incubated in parallel on multiple identical mini-arrays containing identical copies of triplicates of the peptide library combined on one microarray slide where four slides yielded an incubation frame possessing the dimensions of a 96-well microtiter plate and enabling downstream procedure identical to ELISA (S1 File).</s><s>The selection of the peptides was based firstly on the p-value for the comparison of the healthy and the CFS patients, respectively.</s><s>Secondly, peptides with high variances in the signals and negative controls were added.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ELISA</head><p><s>Selected peptides were synthesized containing an additional C-terminal glycine, a spacer molecule and biotin (JPT Peptide Technologies). 100 nM of biotinylated peptide was coated on a 96 well Streptavidin-plate (Nunc Thermo Scientific) for 1 h at RT.</s><s>After blocking for 1 h at 30˚C serum samples were diluted 1:1,000 and 1:10,000 and incubated for 1 h at 30˚C.</s><s>Secondary antibody (anti-human IgG-HRP (goat), Invitrogen) was diluted 1:4,000 and incubated for 1 h at 30˚C, then TMB substrate was added (Sigma Aldrich).</s><s>Plates were measured at Tecan GENios at 620 nm (S1 File).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Detection of EBNA-6 protein</head><p><s>EBNA-6 was expressed in HEK293T cells as C-terminally hexahistidine-tagged full-length protein and purified from cell lysates using Nickel-NTA beads (Qiagen).</s><s>Approximately 50 ng of purified EBNA-6 were spotted onto nitrocellulose membranes (Millipore) and allowed to dry.</s><s>Subsequently, membranes were blocked with 5% skim milk powder in PBS for 1 h before overnight incubation with patient sera diluted 1:1,000 in 3% skim milk/PBS.</s><s>Next day, the membranes were incubated for 1 h with a 1:10,000 dilution of IRDye 800CW goat anti-human IgG (Rockland Immunochemicals) in TBS + 0.05% Tween-20 (TBST) and then washed 4 x 5 min in TBST.</s><s>IR detection was performed with an Odyssey Infrared Imaging System (LI-COR Biosciences) and quantified with the analysis software provided.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>EBV load and calculation of EBER copies</head><p><s>Detection of EBV viral load was done by a quantitative real-time PCR analysis (qPCR) for EBV EBER-1 (Table <ref type="table" target="#tab_1">2</ref>).</s><s>The DNA samples from throat washing samples were obtained by gargling with 10 ml of water and washed twice with PBS.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Detection of EBV type I and II</head><p><s>PCR was performed using primer spanning the EBNA-6 (EBNA-3C) gene (Table <ref type="table" target="#tab_1">2</ref>) as previously described <ref type="bibr" target="#b42">[44]</ref>.</s><s>The primer flank regions in the EBNA-6 gene of type-specific variations resulting in different product fragments with a size of 153 bp for EBV type I and 246 bp for EBV type II. 100 ng DNA template of the throat washing samples were used per reaction.</s><s>The amplified products were investigated by gel electrophoreses analysis in a 2% agarose gel and visualized by ethidium bromide.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>Statistical data analyses were done using R (www.r-project.org) and the software GraphPad Prism 6.0.</s><s>Nonparametric statistical methods were used.</s><s>Continuous variables were expressed as median and interquartile range (IQR).</s><s>Univariate comparisons of two independent groups were done using the Mann-Whitney-U test.</s><s>Contingency analysis was done by Fisher's exact test.</s><s>Correlation analysis was performed by nonparametric Spearman coefficient r.</s><s>A twotailed p-value of &lt;0.05 was considered statistically significant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Antibody reactivity against EBV epitopes</head><p><s>Serum IgG responses of 50 healthy controls, 92 CFS, 30 MS, 30 SLE, and 100 Hodgkin's lymphoma (HD) patients against single overlapping peptides designed as 15-mers of major EBV   intensity against all EBV peptides was higher in the CFS cohort compared to the healthy controls (p&lt;0.05)</s><s>and highest in the MS cohort (p = 3.2 Ã 10 −6 against healthy controls).</s><s>Significant different IgG responses were observed against less than 3% of EBV peptides in CFS compared to healthy controls.</s><s>The signal difference against the EBNA-1 peptides was higher in MS against healthy (p = 2.8 Ã 10 −7 ) but not CFS against healthy (middle panel), whereas no difference was found among the cohorts against enterovirus peptides (lower panel).</s><s>Patients with SLE and patients with HD in disease remission with cancer-related fatigue (HD_NF) or without fatigue (HD_FAT) were analysed in another seroarray experiment (Fig <ref type="figure" target="#fig_3">2B</ref>).</s><s>The signal intensity against all EBV peptides was similar for fatigued compared to non-fatigued Hodgkin patients (upper panel).</s><s>SLE patients had significantly higher signal intensity against all EBV peptides compared to the cancer patients (p = 3 Ã 10 −11 ).</s><s>No or little signal difference was found for the EBNA-1 peptides between the 3 groups (middle panel) while patients with SLE had a higher IgG response to enterovirus peptides (lower panel).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Enhanced antibody reactivity against an EBNA-6 repeat region in CFS patients</head><p><s>Enhanced reactivity in CFS patients was observed against several peptides from the EBNA-6 aa 744-778 region containing a repeat sequence.</s><s>All overlapping peptides containing the conserved sequence QAPYQGYQE of type I EBV peptides of EBNA-6 were recognized with a higher intensity by CFS patients compared to healthy controls in the seroarray (Fig 3A <ref type="figure">, left</ref>).</s><s>The peptides aa 735, 738, and 761 containing a truncated repeat sequence were recognized with lower signal intensity.</s><s>Further, only a small subset of patients and no controls showed an enhanced IgG response against peptides derived from type II EBV peptides of an EBNA-6 region homologue to the repeat region found in type I (Fig 3A <ref type="figure">, right</ref>).</s><s>The repeat sequence QAPYPGYEE varied in two aa.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Prevalence of type I EBV in CFS patients</head><p><s>Throat washing samples as a source of frequent EBV reactivation were collected from 50 CFS patients and 50 healthy donors.</s><s>The samples were measured by qPCR for EBV viral load by calculating copies of EBER per μg template DNA.</s><s>EBER copies were detected in 42% (n = 21) of healthy donors and 30% (n = 15) of CFS patients (Fig <ref type="figure" target="#fig_4">3B</ref>) revealing no significant difference in frequency (p = 0.37).</s><s>Samples of EBER positive patients and controls were further analysed for the prevalence of either EBV type I or II.</s><s>Here a PCR was established using primer spanning the EBNA-6 gene, as previously described <ref type="bibr" target="#b42">[44]</ref>.</s><s>The primers flank regions in the EBNA-6 gene resulting in type-specific products of different sizes (Fig <ref type="figure" target="#fig_4">3C</ref>).</s><s>The resulting fragments after gel electrophoresis show products with a size corresponding to 153 bp for EBV type I (B95.8) in all samples of both patients and controls.</s><s>No signals for EBV type II (AG876) expected at 246 bp were observed.</s><s>No clear product was detected for two CFS patients due to low DNA concentrations and the lowest EBER copy number in the PCR analysis.</s><s>Data from the seroarray are in accordance to our finding of the prevalence of EBV type I in controls and patients.</s><s>We detected significantly enhanced IgG responses in all controls and patients against</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Evidence for enhanced IgG-response against EBNA-6 protein in CFS and potential mimicry with human lactoperoxidase</head><p><s>The enhanced IgG response against the EBNA-6 repeat region of type I EBNA-6 could be confirmed in the multiwell assay in which 128 selected peptides based on the results of the seroarray were tested.</s><s>In both the cohort analysed by seroarray (CFS, n = 93 and healthy, n = 50) and a subsequent validation cohort (CFS, n = 227 and healthy, n = 47) (Fig 4A <ref type="figure">)</ref> we found IgG responses against the EBNA-6 peptide at higher intensities in patients compared to controls.</s><s>Further, the antibody response against EBNA-6_740 containing the repeat region was assessed by a peptide ELISA (Fig 4B <ref type="figure">)</ref> confirming a significantly enhanced antibody response in 162 CFS patients compared to 115 healthy donors (p = 0.02).</s><s>IgG responses &gt;95%ile of healthy controls (OD of 0.882) were found in 14.8% of CFS patients (p = 0.02).</s><s>A peptide which was not recognized in the seroarray was used as negative control.</s></p><p><s>The core sequence of the repeat region of EBNA-6 (QAPYQGYQE) was studied for homologue sequences in human proteins using BLAST the Basic Local Alignment Search (database: UniProtKBSwiss-Prot, sorted by MaxScore) revealing a 7 amino acids homologous region comprising 6 identical amino acids in the human LPO protein sequence (Table <ref type="table">3</ref>).</s><s>Further proteins showing at least 4 amino acid identity to the EBNA-6 repeat region were thyroid peroxidase (TPO), phosphofructokinase (PFK) and the ornithine carbamoyltransferase (OTC).</s><s>All 3 are of interest, because their function may be linked to CFS pathogenesis <ref type="bibr" target="#b63">[65,</ref><ref type="bibr" target="#b64">66]</ref>.</s><s>In a We next analysed IgG responses against EBNA-6 protein in a subset of the patients analysed for EBNA-6 peptide responses.</s><s>We observed significantly enhanced IgG responses against the EBNA-6 protein in CFS patients versus controls as well as a good correlation between recombinant EBNA-6 protein and EBNA-6 peptide IgG (Fig <ref type="figure">4C</ref>).</s></p><p><s>Further IgG responses against recombinant LPO protein as well against PFK-P and OTC proteins were analysed in in a subset of the patients and healthy donors analysed for EBNA-6 peptide responses by ELISA.</s><s>We observed neither clearly enhanced IgG responses nor differences between CFS and healthy controls against these 3 proteins (data not shown).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>In this study we performed a comprehensive analysis of IgG responses against a peptide library of the major EBV proteins.</s><s>In healthy controls we observed the strongest and broadest antibody responses against the latency proteins EBNA-1, -3, -4, and -6, and the lytic proteins BALF2, BALF5, and BZLF1.</s><s>This finding is in accordance with studies analysing the IgG response against EBV proteins in which strong IgG responses against both EBNA proteins and BZLF1 are found and used for serodiagnosis <ref type="bibr" target="#b65">[67]</ref><ref type="bibr" target="#b66">[68]</ref><ref type="bibr" target="#b67">[69]</ref><ref type="bibr" target="#b68">[70]</ref><ref type="bibr" target="#b69">[71]</ref><ref type="bibr" target="#b70">[72]</ref><ref type="bibr" target="#b71">[73]</ref>.</s><s>The strong enhanced IgG response against various EBV proteins in MS and SLE shown in previous studies was confirmed in this and for MS in our prior study <ref type="bibr" target="#b7">[8]</ref>.</s><s>In contrast, although total IgG response against EBV peptides was higher in CFS the pattern of IgG responses was more similar to healthy controls.</s><s>Further, we had performed a subgroup analysis in patients with Hodgkin lymphoma showing no difference in IgG EBV response pattern in patients with and without fatigue.</s></p><p><s>Interestingly, we observed a significantly enhanced IgG response against EBNA-6 peptides spanning a repeat region in CFS patients compared to healthy controls.</s><s>A 21 aa long peptide comprising the repeat region of EBNA-6 was already described by Rajnavo ¨lgyi et al. as a HLA-DR restricted T cell epitope <ref type="bibr" target="#b72">[74]</ref>.</s><s>Further we could show a close correlation between IgG responses against EBNA-6 peptide and a recombinant EBNA-6 protein suggesting that this peptide is recognized in the protein and is an immunodominant epitope.</s><s>If the enhanced IgG response against EBNA-6 may be of diagnostic relevance in a subgroup of patients needs to be analysed in a longitudinal study.</s><s>Cross-reactivity of EBV-specific IgG with human antigens due to antigenic mimicry is known to trigger pathogenic immune responses in SLE and MS <ref type="bibr" target="#b73">[75]</ref><ref type="bibr" target="#b74">[76]</ref><ref type="bibr" target="#b75">[77]</ref>.</s><s>We thus performed a sequence comparison of the EBNA-6 repeat region with human proteins and identified a 7 amino acids homologous sequence in the LPO protein, an enzyme producing oxidants and secreted by mammary, salivary and mucous glands of the bronchia.</s><s>LPO is involved in immune defence with broad activity against bacteria and viruses <ref type="bibr" target="#b76">[78]</ref><ref type="bibr" target="#b77">[79]</ref><ref type="bibr" target="#b78">[80]</ref>.</s><s>Interestingly, we detected a correlation of EBNA-6 peptide and protein IgG with LPO peptide IgG levels.</s><s>However, we observed no elevated levels of LPO protein IgG in patients with CFS suggesting that the peptide is not recognized in the recombinant protein.</s><s>Interestingly, human TPO shows a sequence homology with 5 (comprising 4 identical aa) of the 7 amino acids of the EBNA-6 repeat region as well.</s><s>Autoantibodies against TPO and hashimoto's thyroiditis are detected in 10-20% of patients with CFS and lead to thyroid destruction through antibody dependent cellular cytotoxicity and complement activation <ref type="bibr" target="#b79">[81]</ref>.</s><s>We could, however, not observe elevated IgG responses against the TPO peptide in our study.</s><s>Two other proteins showing homology to the EBNA-6 repeat region, the enzymes OTC and PFK arouse our interest because of their metabolic function (Table <ref type="table">3</ref>).</s><s>Data from Yamano et al. revealed higher ornithine/citrulline ratio in CFS patient which could be explained by reduced OTC activity <ref type="bibr" target="#b64">[66]</ref>.</s><s>The PFK catalyses the rate limiting step of glycolysis and inhibition of the enzyme could play a role in metabolic alterations in CFS <ref type="bibr" target="#b63">[65,</ref><ref type="bibr" target="#b64">66]</ref>.</s><s>However, as for LPO protein, we observed no reactivity of CFS patients against these two proteins.</s></p><p><s>There exist two major EBV subtypes type I and type II EBV with sequence variations in several EBV proteins.</s><s>The prevalence of EBV serotypes varies in different geographic regions <ref type="bibr" target="#b49">[51]</ref>.</s><s>While healthy subjects usually are resistant to coinfection with another subtype, in immunodeficiency infection with two EBV types is frequently found <ref type="bibr" target="#b80">[82,</ref><ref type="bibr" target="#b81">83]</ref>.</s><s>In our study, there was a significantly lower IgG response against peptides from type II specific regions compared to type I specific regions in both CFS patients and controls.</s><s>EBV frequently reactivates in the oropharynx and can be detected in throat washing samples in 20-70% in healthy donors <ref type="bibr" target="#b82">[84,</ref><ref type="bibr" target="#b83">85]</ref>.</s><s>Our data show a similar prevalence of EBV reactivation in 30-40% of samples and the infection with type I EBV in both healthy controls and CFS patients providing no evidence for EBV coinfection or prevalence of another EBV serotype in CFS patients.</s><s>The prevalence of EBV type I is in accordance with another study showing that it is more frequent in northern countries <ref type="bibr" target="#b49">[51]</ref>.</s><s>The observed antibody responses against peptides derived from sequences of EBV type II strains might be due to cross reactivity.</s></p><p><s>In conclusion, we could show the suitability of the EBV peptide microarray to analyse the seroresponse against EBV.</s><s>Further, we could identify multiple peptide epitopes of EBV proteins recognized in healthy controls and patients.</s><s>Our seroarray data and the similar prevalence of EBV in throat washings in CFS compared to healthy controls, argue against a pathogenic role of EBV reactivation in CFS.</s><s>The enhanced IgG response against an EBNA-6 repeat sequence may point to a potential antigenic mimicry and requires further studies.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supporting information</head><note type="other">S1</note></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>The pellet was resuspended in 200 μl of AL-Lysis buffer (QIAamp DNA Blood mini Kit from QIAGEN) for DNA preparation according to manufacturer's instructions.</s><s>100 ng DNA template per reaction was added to a final volume of 25 μl.</s><s>A dilution series of Namalwa DNA, a positive EBV cell line with known EBER copies per specific amount of Namalwa DNA, was used as positive control and to calculate the EBER copies per μg DNA/cDNA of each analysed sample.</s><s>Results over 35 EBER copies per template DNA or cDNA were regarded as positive.</s><s>Duplicate measurements of each sample were performed on a 7500 Real Time PCR System (Applied Biosystems Life Technologies).</s><s>The amplification was performed at 42 cycles with 2 min 50˚C, 10 min 95˚C and 15 sec 95˚C and finally 1 min at 60˚C.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig 1 .</head><label>1</label><figDesc><div><p><s>Fig 1. Seroarray analysis of IgG antibody reactivity against 15-mer EBV peptides which cover 14 EBV proteins with sequences of EBV type I (B-95.8) in 50 healthy donors.</s><s>IgG responses of each sample against each peptide are depicted.</s><s>Responses are defined as a signal intensity above 5,000.</s><s>In the left graph the % of samples with a response against each single peptide of the indicated proteins are shown.</s><s>The right graph shows the mean intensity of these IgG responses (defined as a signal intensity above 5,000) against the single peptides.</s><s>EA-early antigen; PM-polymerase; VCA-viral capsid antigen; gp-glycoprotein.</s><s>https://doi.org/10.1371/journal.pone.0179124.g001</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc><div><p><s>signal</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig 2 .</head><label>2</label><figDesc><div><p><s>Fig 2. Total IgG responses against EBV, EBNA-1 and enterovirus peptides in the different cohorts.</s><s>A) The signal intensity of IgG responses against all EBV peptides (upper row), EBNA-1 peptides (middle row) and enterovirus (lower row) in CFS, healthy controls and MS patients.</s><s>B) Comparison of patients with SLE and Hodgkin's lymphoma in disease remission with cancer-related fatigue (HD_NF) or without fatigue (HD_FAT) analysed in another seroarray screening experiment.</s><s>Statistical analysis by Wilcoxon rank sum test with * p&lt;0.05, *** p &lt;0.001.</s><s>https://doi.org/10.1371/journal.pone.0179124.g002</s></p></div></figDesc><graphic coords="8,200.01,78.01,366.63,522.14" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Fig 3 .</head><label>3</label><figDesc><div><p><s>Fig 3. Reactivity against EBV type I EBNA-6.</s><s>A) Seroarray data showing signal intensities for healthy controls (n = 50) and CFS patients (n = 92) against peptides from repeat region of EBNA-6_731-780 from strain B95.8 of type I EBV (left) and EBNA-6_770-805 from strain AG876 of type II EBV (right) containing the repeat sequence QAPYQGYQE.</s><s>B) EBER copies were determined by qPCR of EBER-1 in throat washing samples of 50 healthy controls and CFS patients.</s><s>C) EBER positive samples were tested for EBNA-6 DNA with primers discriminating EBV type I (B95.8) and II (AG876) by PCR.</s><s>Gel electrophoresis shows 153 bp products corresponding to type I. Product of type II has an estimated size of 246 bp.</s><s>As positive control (+) EBV type I cell line Namalwa DNA, as negative control (-) water was used instead of template DNA.</s><s>D) Unique EBNA-6 peptides for EBV serotypes I (B95.8) and II (AG876) were compared for specific IgG response in 50 controls (NOR) and 92 CFS patients (CFS) by seroarray.</s><s>Shown are EBNA-6 peptides that induced an IgG response of &gt;5000 U in healthy controls (see S2 File).</s><s>M-DNA ladder.</s><s>Statistical analysis by Mann-Whitney-U test with n.s.-not significant, * p&lt;0.05, ** p&lt;0.01.</s><s>https://doi.org/10.1371/journal.pone.0179124.g003</s></p></div></figDesc><graphic coords="9,200.01,78.01,323.21,261.30" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Fig 4 .Table 3 .</head><label>43</label><figDesc><div><p><s>Fig 4. Reactivity against EBNA-6, LPO and TPO in CFS patients.</s><s>A) Median intensity of IgG response against EBNA-6 peptide 740 in seroarray cohort (CFS, n = 93 and healthy, n = 50) and a subsequent validation cohort (CFS, n = 227 and healthy, n = 47) was analysed by multiwell assay.</s><s>B) Optical density (OD) and Interquartile Range (IQR) of IgG response against EBNA6_740, a negative control peptide, LPO, and TPO in healthy controls (n = 115) and CFS patients (n = 162) by peptide ELISA.</s><s>C) Correlation of ELISA OD values of EBNA6_740 and LPO for all patients and controls.</s><s>D) IgG responses against EBNA-6 protein in in healthy controls (n = 40) and CFS patients (n = 40) detected by Odyssey Infrared Imaging System as arbitrary fluorescence units (AFU), and correlation of EBNA-6 protein and EBNA-6 peptide as well as LPO peptide IgG in CFS patients.</s><s>Statistical analysis by two-tailed Mann-Whitney-U test with * p&lt;0.05, ** p&lt;0.01, *** p &lt;0.001, **** p&lt;0.0001, r-spearman coefficient.</s><s>https://doi.org/10.1371/journal.pone.0179124.g004</s></p></div></figDesc><graphic coords="10,39.57,78.01,536.32,285.51" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head></head><label></label><figDesc><div><p><s>File.</s><s>Raw data of peptide seroarray, multiwell array and peptide ELISA.</s><s>(XLSX) S2 File.</s><s>EBNA-6 type I and type II specific peptide sequences shown in Fig 2D.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>Formal analysis :</head><label>analysis</label><figDesc><div><p><s>ML ME PG UR UB CS.</s><s>Funding acquisition: UR CS.</s><s>Investigation: ML ME EH SB PG JZ PH LGH KW CM FS.</s><s>Methodology: ML ME EH SB PG JZ PH LGH KW CM UR CS.</s><s>Project administration: UR CS.</s><s>Resources: PB JUR FH KR HDV UB UR CS.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 . Demographic characteristics. Variable CFS Peptide Array (n = 92) CFS Multiwell Array (n = 328) CFS ELISA (n = 162) Controls (n = 115)</head><label>1</label><figDesc></figDesc><table><row><cell>Age (years)</cell><cell>43 ± 12</cell><cell>43 ± 11</cell><cell>43 ± 11</cell><cell>36 ± 10</cell></row><row><cell>m/f (%)</cell><cell>50/ 50</cell><cell>39/ 61</cell><cell>42/ 58</cell><cell>42/ 58</cell></row><row><cell>Bell score</cell><cell>30 ± 10</cell><cell>30 ± 10</cell><cell>30 ± 10</cell><cell>n.a.</cell></row><row><cell>n.a. not applicable</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">https://doi.org/10.1371/journal.pone.0179124.t001</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 . Primer and probe for EBV load and type PCR.</head><label>2</label><figDesc></figDesc><table /></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">PLOS ONE | https://doi.org/10.1371/journal.pone.0179124June 12, 2017  </note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0" />			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">EBV and systemic lupus erythematosus: a new perspective</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Gross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hochberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Rand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Thorley-Lawson</surname></persName>
		</author>
		<idno type="PMID">15905498</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of immunology</title>
		<imprint>
			<biblScope unit="volume">174</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="6599" to="6607" />
			<date type="published" when="1950">1950. 2005. 2005/05/21</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">I</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Quan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nolasco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Crouch</surname></persName>
		</author>
		<idno type="PMID">14707107</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of immunology</title>
		<imprint>
			<biblScope unit="volume">172</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="1287" to="1294" />
			<date type="published" when="1950">1950. 2004. 2004/01/07</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction</title>
		<author>
			<persName><forename type="first">N</forename><surname>Balandraud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Meynard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Auger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sovran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Mugnier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Reviron</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.10933</idno>
		<idno type="PMID">12746895</idno>
		<ptr target="https://doi.org/10.1002/art.10933" />
	</analytic>
	<monogr>
		<title level="j">Arthritis and rheumatism</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1223" to="1228" />
			<date type="published" when="2003-05-15">2003. 2003/05/15</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Epstein-Barr virus infection in peripheral blood mononuclear cells, synovial fluid cells, and synovial membranes of patients with rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Blaschke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Schwarz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Moneke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Binder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Reuss-Borst</surname></persName>
		</author>
		<idno type="PMID">10782808</idno>
	</analytic>
	<monogr>
		<title level="j">The Journal of rheumatology</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="866" to="873" />
			<date type="published" when="2000-04-27">2000. 2000/04/27</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">EBV reactivation serological profile in primary Sjogren&apos;s syndrome: an underlying trigger of active articular involvement?</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Pasoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Natalino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Chakkour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Viana</forename><surname>Vdos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bueno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Leon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename></persName>
		</author>
		<idno type="DOI">10.1007/s00296-012-2504-3</idno>
		<idno type="PMID">22955798</idno>
		<ptr target="https://doi.org/10.1007/s00296-012-2504-3" />
	</analytic>
	<monogr>
		<title level="j">Rheumatology international</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1149" to="1157" />
			<date type="published" when="2012-09-08">2013. 2012/09/08</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Epstein-Barr virus and multiple sclerosis: potential opportunities for immunotherapy</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Pender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Burrows</surname></persName>
		</author>
		<idno type="DOI">10.1038/cti.2014.25</idno>
		<idno type="PMID">25505955</idno>
		<idno>PMCID: PMCPmc4237030</idno>
		<ptr target="https://doi.org/10.1038/cti.2014.25" />
	</analytic>
	<monogr>
		<title level="j">Clinical &amp; translational immunology</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">10</biblScope>
			<date type="published" when="2014">2014. 2014/12/17</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Handel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Williamson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Disanto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Handunnetthi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Giovannoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">V</forename><surname>Ramagopalan</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0012496</idno>
		<idno type="PMID">20824132</idno>
		<idno>PMCID: PMCPmc2931696</idno>
		<ptr target="https://doi.org/10.1371/journal.pone.0012496" />
	</analytic>
	<monogr>
		<title level="j">PloS one</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">9</biblScope>
			<date type="published" when="2010-09-09">2010. 2010/09/09</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Multiple sclerosis: The elevated antibody response to Epstein-Barr virus primarily targets, but is not confined to, the glycine-alanine repeat of Epstein-Barr nuclear antigen-1</title>
		<author>
			<persName><forename type="first">K</forename><surname>Ruprecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wunderlich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Giess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Loebel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Lenz</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jneuroim.2014.04.005</idno>
		<idno type="PMID">24798244</idno>
		<ptr target="https://doi.org/10.1016/j.jneuroim.2014.04.005" />
	</analytic>
	<monogr>
		<title level="j">Journal of neuroimmunology</title>
		<imprint>
			<date type="published" when="2014-05-07">2014. 2014/05/07</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">A</forename><surname>Ascherio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Munger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Autoimmunity</forename><surname>Ebv</surname></persName>
		</author>
		<idno type="DOI">10.1007/978-3-319-22822-8_15</idno>
		<idno type="PMID">26424654</idno>
		<ptr target="https://doi.org/10.1007/978-3-319-22822-8_15" />
	</analytic>
	<monogr>
		<title level="j">Curr Top Microbiol Immunol</title>
		<imprint>
			<biblScope unit="volume">390</biblScope>
			<biblScope unit="page" from="365" to="385" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Combinatorial antibody library from multiple sclerosis patients reveals antibodies that cross-react with myelin basic protein and EBV antigen</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Gabibov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Belogurov</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">A</forename><surname>Lomakin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Zakharova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Avakyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">V</forename><surname>Dubrovskaya</surname></persName>
		</author>
		<idno type="DOI">10.1096/fj.11-190769</idno>
		<idno type="PMID">21859892</idno>
		<ptr target="https://doi.org/10.1096/fj.11-190769" />
	</analytic>
	<monogr>
		<title level="j">Faseb j</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="4211" to="4221" />
			<date type="published" when="2011">2011. 2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Cross-reactivity of autoreactive T cells with MBP and viral antigens in patients with MS</title>
		<author>
			<persName><forename type="first">W</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Gong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Huang</surname></persName>
		</author>
		<idno type="PMID">22201827</idno>
	</analytic>
	<monogr>
		<title level="j">Front Biosci</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1648" to="1658" />
			<date type="published" when="2011">2012. 2011/12/29</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Lupus-like autoantibody development in rabbits and mice after immunization with EBNA-1 fragments</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Poole</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Maier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Harley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>James</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jaut.2008.08.007</idno>
		<idno type="PMID">18849143</idno>
		<idno>PMCID: PMCPmc2852321</idno>
		<ptr target="https://doi.org/10.1016/j.jaut.2008.08.007" />
	</analytic>
	<monogr>
		<title level="j">J Autoimmun</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="362" to="371" />
			<date type="published" when="2008-10-14">2008. 2008/10/14</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<ptr target="http://wwwcdcgov/cfs/indexhtml" />
	</analytic>
	<monogr>
		<title level="m">Chronic Fatigue Syndrome (CFS)</title>
				<imprint>
			<date type="published" when="2015-06">June 2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Myalgic encephalomyelitis: International Consensus Criteria</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Carruthers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Van De Sande</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Meirleir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Klimas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Broderick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mitchell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename></persName>
		</author>
		<idno type="DOI">10.1111/j.1365-2796.2011.02428.x</idno>
		<idno type="PMID">21777306</idno>
		<idno type="PMCID">PMC3427890</idno>
		<ptr target="https://doi.org/10.1111/j.1365-2796.2011.02428.x" />
	</analytic>
	<monogr>
		<title level="j">Journal of internal medicine</title>
		<imprint>
			<biblScope unit="volume">270</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="327" to="338" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">The neuropsychiatric and neuropsychological features of chronic fatigue syndrome: revisiting the enigma</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Christley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Duffy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">P</forename><surname>Everall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Martin</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11920-013-0353-8</idno>
		<idno type="PMID">23440559</idno>
		<ptr target="https://doi.org/10.1007/s11920-013-0353-8" />
	</analytic>
	<monogr>
		<title level="j">Curr Psychiatry Rep</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">4</biblScope>
			<date type="published" when="2013-02-27">2013. 2013/02/ 27</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Chronic fatigue syndrome, the immune system and viral infection</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Bansal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Bradley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">N</forename><surname>Bishop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kiani-Alikhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ford</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.bbi.2011.06.016</idno>
		<idno type="PMID">21756995</idno>
		<ptr target="https://doi.org/10.1016/j.bbi.2011.06.016" />
	</analytic>
	<monogr>
		<title level="j">Brain, behavior, and immunity</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="24" to="31" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Editorial on CFS was biased, inaccurate, and misleading</title>
		<author>
			<persName><forename type="first">C</forename><surname>Shepherd</surname></persName>
		</author>
		<idno type="PMID">11950748</idno>
		<idno>PMCID: PMCPmc1122848</idno>
	</analytic>
	<monogr>
		<title level="j">Bmj</title>
		<imprint>
			<biblScope unit="volume">324</biblScope>
			<biblScope unit="issue">7342</biblScope>
			<biblScope unit="page">914</biblScope>
			<date type="published" when="2002-04-16">2002. 2002/04/16</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Symptom occurrence in persons with chronic fatigue syndrome</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Jason</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Torres-Harding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Carrico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Taylor</surname></persName>
		</author>
		<idno type="PMID">11790441</idno>
	</analytic>
	<monogr>
		<title level="j">Biol Psychol</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="15" to="27" />
			<date type="published" when="2002-01-16">2002. 2002/01/16</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Chronisches Fatigue Syndrom: Heutige Vorstellungen zur Pathogenese, Diagnostik und Therapie/ Chronic Fatigue Syndrom: current concepts in pathogenesis, diagnostic approaches and treatment</title>
		<author>
			<persName><forename type="first">C</forename><surname>Scheibenbogen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Volk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Grabowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wittke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Giannini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hoffmeister</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Internistische Praxis</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="335" to="342" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Chronic fatigue syndrome is associated with diminished intracellular perforin</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Maher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Klimas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Fletcher</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1365-2249.2005.02935.x</idno>
		<idno type="PMID">16297163</idno>
		<idno>PMCID: PMCPmc1440524</idno>
		<ptr target="https://doi.org/10.1111/j.1365-2249.2005.02935" />
	</analytic>
	<monogr>
		<title level="j">Clin Exp Immunol</title>
		<imprint>
			<biblScope unit="volume">142</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="505" to="511" />
			<date type="published" when="2005">2005. 2005/11/22</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Chronic fatigue syndrome: an examination of the phases</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Jason</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Fricano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Halpert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Fennell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Klein</surname></persName>
		</author>
		<idno type="DOI">10.1002/1097-4679(200012)56:12&lt;1497::AID-2&gt;3.0.CO;2-Z</idno>
		<idno type="PMID">11132566</idno>
		<ptr target="https://doi.org/10.1002/1097-4679" />
	</analytic>
	<monogr>
		<title level="j">J Clin Psychol</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1497" to="1508" />
			<date type="published" when="2000">2000. 2001/01/02. 200012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Brenu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Van Driel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Staines</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Ashton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Ramos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Keane</surname></persName>
		</author>
		<idno type="DOI">10.1186/1479-5876-9-81</idno>
		<idno type="PMID">21619669</idno>
		<idno>PMCID: PMCPmc3120691</idno>
		<ptr target="https://doi.org/10.1186/1479-5876-9-81" />
	</analytic>
	<monogr>
		<title level="j">Journal of translational medicine</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<date type="published" when="2011-05-31">2011. 2011/05/31</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<monogr>
		<title level="m" type="main">Chronic mononucleosis syndrome. Southern medical journal</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Dubois</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Seeley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Brus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sakamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ballow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Harada</surname></persName>
		</author>
		<idno type="PMID">6093268</idno>
		<imprint>
			<date type="published" when="1984">1984. 1984/11/01</date>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="page" from="1376" to="1382" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<monogr>
		<title level="m" type="main">The &apos;chronic mononucleosis&apos; syndromes. Hospital practice (Office ed)</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Komaroff</surname></persName>
		</author>
		<idno type="PMID">3034937</idno>
		<imprint>
			<date type="published" when="1987-05-30">1987. 1987/05/30</date>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="71" to="75" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Acyclovir treatment of the chronic fatigue syndrome. Lack of efficacy in a placebo-controlled trial</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Straus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Dale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tobi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lawley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Preble</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Blaese</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJM198812293192602</idno>
		<idno type="PMID">2849717</idno>
		<ptr target="https://doi.org/10.1056/NEJM198812293192602" />
	</analytic>
	<monogr>
		<title level="j">The New England journal of medicine</title>
		<imprint>
			<biblScope unit="volume">319</biblScope>
			<biblScope unit="issue">26</biblScope>
			<biblScope unit="page" from="1692" to="1698" />
			<date type="published" when="1988">1988. 1988/12/29</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Lerner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Beqaj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Deeter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Fitzgerald</surname></persName>
		</author>
		<idno type="PMID">18019402</idno>
	</analytic>
	<monogr>
		<title level="j">In vivo</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="707" to="713" />
			<date type="published" when="2007">2007. 2007/11/21</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Montoya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Kogelnik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bhangoo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Lunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Flamand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Merrihew</surname></persName>
		</author>
		<idno type="DOI">10.1002/jmv.23713</idno>
		<idno type="PMID">23959519</idno>
		<ptr target="https://doi.org/10.1002/jmv.23713" />
	</analytic>
	<monogr>
		<title level="j">Journal of medical virology</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="2101" to="2109" />
			<date type="published" when="2013-08-21">2013. 2013/08/21</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Straus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Tosato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Armstrong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lawley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">T</forename><surname>Preble</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Henle</surname></persName>
		</author>
		<idno type="PMID">2578268</idno>
	</analytic>
	<monogr>
		<title level="j">Annals of internal medicine</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="7" to="16" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<title level="m" type="main">Antibodies to Epstein-Barr virus-specific DNase and DNA polymerase in the chronic fatigue syndrome. Archives of internal medicine</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Schooley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Glaser</surname></persName>
		</author>
		<idno type="PMID">2843138</idno>
		<imprint>
			<date type="published" when="1988">1988</date>
			<biblScope unit="volume">148</biblScope>
			<biblScope unit="page" from="1957" to="1960" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Frequency of &apos;chronic active Epstein-Barr virus infection&apos; in a general medical practice</title>
		<author>
			<persName><forename type="first">D</forename><surname>Buchwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Sullivan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Komaroff</surname></persName>
		</author>
		<idno type="PMID">3033338</idno>
	</analytic>
	<monogr>
		<title level="j">Jama</title>
		<imprint>
			<biblScope unit="volume">257</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="2303" to="2307" />
			<date type="published" when="1987-05-01">1987. 1987/05/01</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Chronic fatigue syndrome and the diagnostic utility of antibody to Epstein-Barr virus early antigen</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Hellinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Van Scoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Spitzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Forgacs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Edson</surname></persName>
		</author>
		<idno type="PMID">2840523</idno>
	</analytic>
	<monogr>
		<title level="j">Jama</title>
		<imprint>
			<biblScope unit="volume">260</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="971" to="973" />
			<date type="published" when="1988-08-19">1988. 1988/08/19</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">A cluster of patients with a chronic mononucleosis-like syndrome. Is Epstein-Barr virus the cause?</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">P</forename><surname>Holmes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Stewart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Pinsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Schonberger</surname></persName>
		</author>
		<idno type="PMID">3033337</idno>
	</analytic>
	<monogr>
		<title level="j">Jama</title>
		<imprint>
			<biblScope unit="volume">257</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="2297" to="2302" />
			<date type="published" when="1987-05-01">1987. 1987/05/01</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">IgM serum antibodies to Epstein-Barr virus are uniquely present in a subset of patients with the chronic fatigue syndrome</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Lerner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Beqaj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Deeter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Fitzgerald</surname></persName>
		</author>
		<idno type="PMID">15113035</idno>
	</analytic>
	<monogr>
		<title level="j">In Vivo</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="101" to="106" />
			<date type="published" when="2004-04-29">2004. 2004/04/29</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Antibody to Epstein-Barr virus deoxyuridine triphosphate nucleotidohydrolase and deoxyribonucleotide polymerase in a chronic fatigue syndrome subset</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Lerner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Ariza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jason</forename><forename type="middle">L</forename><surname>Beqaj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fitzgerald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0047891</idno>
		<idno type="PMID">23155374</idno>
		<idno>PMCID: PMCPmc3498272</idno>
		<ptr target="https://doi.org/10.1371/journal.pone.0047891" />
	</analytic>
	<monogr>
		<title level="j">PloS one</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">11</biblScope>
			<date type="published" when="2012">2012. 2012/11/17</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Antibody responses to Epstein-Barr virus, human herpesvirus 6 and human herpesvirus 7 in patients with chronic fatigue syndrome</title>
		<author>
			<persName><forename type="first">T</forename><surname>Sairenji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yamanishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tachibana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bertoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kurata</surname></persName>
		</author>
		<idno type="PMID">8724857</idno>
	</analytic>
	<monogr>
		<title level="j">Intervirology</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="269" to="273" />
			<date type="published" when="1995-01-01">1995. 1995/01/01</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Studies on the relationship between chronic fatigue syndrome and Epstein-Barr virus in Japan</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kawai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kawai</surname></persName>
		</author>
		<idno type="PMID">1319246</idno>
	</analytic>
	<monogr>
		<title level="j">Intern Med</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="313" to="318" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Serological and virological investigation of the role of the herpesviruses EBV, CMV and HHV-6 in post-infective fatigue syndrome</title>
		<author>
			<persName><forename type="first">B</forename><surname>Cameron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Flamand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Juwana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Middeldorp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Naing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Rawlinson</surname></persName>
		</author>
		<idno type="DOI">10.1002/jmv.21873</idno>
		<idno type="PMID">20827765</idno>
		<ptr target="https://doi.org/10.1002/jmv.21873" />
	</analytic>
	<monogr>
		<title level="j">J Med Virol</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1684" to="1688" />
			<date type="published" when="2010-09-10">2010. 2010/09/10</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Human herpesviruses in chronic fatigue syndrome</title>
		<author>
			<persName><surname>Wallace Hl 2nd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Natelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Gause</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hay</surname></persName>
		</author>
		<idno type="PMID">10066657</idno>
		<idno>PMCID: PMCPmc95690</idno>
	</analytic>
	<monogr>
		<title level="j">Clin Diagn Lab Immunol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="216" to="223" />
			<date type="published" when="1999-03-06">1999. 1999/03/06</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Epstein-Barr virus infection, musculoskeletal pain, and depressive symptoms in chronic fatigue syndrome</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Whelton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Salit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Moldofsky</surname></persName>
		</author>
		<author>
			<persName><surname>Sleep</surname></persName>
		</author>
		<idno type="PMID">1328633</idno>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="939" to="943" />
			<date type="published" when="1992-06-01">1992. 1992/06/01</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Deficient EBV-specific Band T-cell response in patients with chronic fatigue syndrome</title>
		<author>
			<persName><forename type="first">M</forename><surname>Loebel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Strohschein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Giannini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Koelsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Doebis</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0085387</idno>
		<idno type="PMID">24454857</idno>
		<idno>PMCID: PMCPmc3893202</idno>
		<ptr target="https://doi.org/10.1371/journal.pone.0085387" />
	</analytic>
	<monogr>
		<title level="j">PloS one</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">1</biblScope>
			<date type="published" when="2014-01-24">2014. 2014/01/24</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Antibody responses to two Epstein-Barr virus nuclear antigens defined by gene transfer</title>
		<author>
			<persName><forename type="first">G</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Grogan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Niederman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Schooley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Henle</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJM198503213121204</idno>
		<idno type="PMID">2983211</idno>
		<ptr target="https://doi.org/10.1056/NEJM198503213121204" />
	</analytic>
	<monogr>
		<title level="j">The New England journal of medicine</title>
		<imprint>
			<biblScope unit="volume">312</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="750" to="755" />
			<date type="published" when="1985-03-21">1985. 1985/03/21</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection</title>
		<author>
			<persName><forename type="first">W</forename><surname>Henle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Henle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Andersson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Ernberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Horwitz</surname></persName>
		</author>
		<idno type="PMID">3025881</idno>
		<idno>PMCID: PMCPmc304252</idno>
	</analytic>
	<monogr>
		<title level="j">Proceedings of the National Academy of Sciences of the United States of America</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="570" to="574" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes</title>
		<author>
			<persName><forename type="first">J</forename><surname>Sample</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Chatman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kieff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rickinson</surname></persName>
		</author>
		<idno type="PMID">2166806</idno>
		<idno>PMCID: PMCPmc247870</idno>
	</analytic>
	<monogr>
		<title level="j">J Virol</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="4084" to="4092" />
			<date type="published" when="1990-09-01">1990. 1990/09/ 01</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Comparison of Epstein-Barr virus strains of different origin by analysis of the viral DNAs</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Bornkamm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Delius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Zimber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hudewentz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Epstein</surname></persName>
		</author>
		<idno type="PMID">6252328</idno>
		<idno>PMCID: PMCPmc288854</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of virology</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="603" to="618" />
			<date type="published" when="1980-09-01">1980. 1980/09/01</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">DNA sequence and expression of the B95-8 Epstein-Barr virus genome</title>
		<author>
			<persName><forename type="first">R</forename><surname>Baer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Bankier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Biggin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Deininger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Farrell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Gibson</surname></persName>
		</author>
		<idno type="PMID">6087149</idno>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">310</biblScope>
			<biblScope unit="issue">5974</biblScope>
			<biblScope unit="page" from="207" to="211" />
			<date type="published" when="1984-07-19">1984. 1984/07/19</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Persistent productive Epstein-Barr virus replication in normal epithelial cells in vivo</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Walling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Flaitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Nichols</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Hudnall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Adler-Storthz</surname></persName>
		</author>
		<idno type="DOI">10.1086/323992</idno>
		<idno type="PMID">11740724</idno>
		<ptr target="https://doi.org/10.1086/323992" />
	</analytic>
	<monogr>
		<title level="j">The Journal of infectious diseases</title>
		<imprint>
			<biblScope unit="volume">184</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1499" to="1507" />
			<date type="published" when="2001">2001. 2001/12/12</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Epstein-Barr virus replication in tongue epithelial cells</title>
		<author>
			<persName><forename type="first">K</forename><surname>Herrmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Frangou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Middeldorp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Niedobitek</surname></persName>
		</author>
		<idno type="DOI">10.1099/0022-1317-83-12-2995</idno>
		<idno type="PMID">12466475</idno>
	</analytic>
	<monogr>
		<title level="j">The Journal of general virology</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="2995" to="2998" />
			<date type="published" when="2002">2002. 2002/12/06</date>
		</imprint>
	</monogr>
	<note>Pt 12</note>
</biblStruct>

<biblStruct xml:id="b47">
	<monogr>
		<title level="m" type="main">Epstein-Barr virus (EBV) infection in epithelial cells in vivo: rare detection of EBV replication in tongue mucosa but not in salivary glands. The Journal of infectious diseases</title>
		<author>
			<persName><forename type="first">P</forename><surname>Frangou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Buettner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Niedobitek</surname></persName>
		</author>
		<idno type="DOI">10.1086/426823</idno>
		<idno type="PMID">15609234</idno>
		<ptr target="https://doi.org/10.1086/426823" />
		<imprint>
			<date type="published" when="2004">2005. 2004/12/21</date>
			<biblScope unit="volume">191</biblScope>
			<biblScope unit="page" from="238" to="242" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Replication of Epstein-Barr virus within the epithelial cells of oral &quot;hairy&quot; leukoplakia, an AIDS-associated lesion</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Greenspan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Greenspan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>Lennette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">I</forename><surname>Abrams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Conant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Petersen</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJM198512193132502</idno>
		<idno type="PMID">2999595</idno>
		<ptr target="https://doi.org/10.1056/NEJM198512193132502" />
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">313</biblScope>
			<biblScope unit="issue">25</biblScope>
			<biblScope unit="page" from="1564" to="1571" />
			<date type="published" when="1985">1985. 1985/12/19</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Epstein-Barr virus replication in oropharyngeal epithelial cells</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Sixbey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Nedrud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Raab-Traub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Hanes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Pagano</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJM198405103101905</idno>
		<idno type="PMID">6323983</idno>
		<ptr target="https://doi.org/10.1056/NEJM198405103101905" />
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">310</biblScope>
			<biblScope unit="issue">19</biblScope>
			<biblScope unit="page" from="1225" to="1230" />
			<date type="published" when="1984-05-10">1984. 1984/05/10</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV</title>
		<author>
			<persName><forename type="first">K</forename><surname>Nilsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Henle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Henle</surname></persName>
		</author>
		<idno type="PMID">4332899</idno>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="443" to="450" />
			<date type="published" when="1971">1971</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells</title>
		<author>
			<persName><forename type="first">J</forename><surname>Yates</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Warren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Reisman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Sugden</surname></persName>
		</author>
		<idno type="PMID">6328526</idno>
		<idno>PMCID: PMCPmc345309</idno>
	</analytic>
	<monogr>
		<title level="j">Proceedings of the National Academy of Sciences of the United States of America</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="3806" to="3810" />
			<date type="published" when="1984-06-01">1984. 1984/06/01</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Transcriptional activation by EBV nuclear antigen 1 is essential for the expression of EBV&apos;s transforming genes</title>
		<author>
			<persName><forename type="first">M</forename><surname>Altmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ruiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Sugden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Hammerschmidt</surname></persName>
		</author>
		<idno type="DOI">10.1073/pnas.0605985103</idno>
		<idno type="PMID">16966603</idno>
		<idno>PMCID: PMCPmc1599932</idno>
		<ptr target="https://doi.org/10.1073/pnas.0605985103" />
	</analytic>
	<monogr>
		<title level="j">Proceedings of the National Academy of Sciences of the United States of America</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="issue">38</biblScope>
			<biblScope unit="page" from="14188" to="14193" />
			<date type="published" when="2006-09-13">2006. 2006/ 09/13</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">EBV persistence in memory B cells in vivo</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Babcock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Decker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Volk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Thorley-Lawson</surname></persName>
		</author>
		<idno type="PMID">9768759</idno>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="395" to="404" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">The biology of Epstein-Barr virus: lessons learned from the virus and the host</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Cohen</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0952-7915(99)80062-4</idno>
		<idno type="PMID">10448133</idno>
		<ptr target="https://doi.org/10.1016/" />
	</analytic>
	<monogr>
		<title level="j">Curr Opin Immunol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="365" to="370" />
			<date type="published" when="1999-08-17">1999. 1999/08/17</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Epstein-Barr virus-associated lymphoproliferative disorders</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Rezk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Weiss</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.humpath.2007.05.020</idno>
		<idno type="PMID">17707260</idno>
		<ptr target="https://doi.org/10.1016/j.humpath.2007.05.020" />
	</analytic>
	<monogr>
		<title level="j">Hum Pathol</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1293" to="1304" />
			<date type="published" when="2007-08-21">2007. 2007/08/21</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Interaction of Epstein-Barr virus (EBV) with human B-lymphocytes</title>
		<author>
			<persName><forename type="first">G</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kashuba</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.bbrc.2010.02.146</idno>
		<idno type="PMID">20494113</idno>
		<ptr target="https://doi.org/10.1016/j.bbrc.2010.02.146" />
	</analytic>
	<monogr>
		<title level="j">Biochem Biophys Res Commun</title>
		<imprint>
			<biblScope unit="volume">396</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="67" to="73" />
			<date type="published" when="2010-05-25">2010. 2010/05/25</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Latent and lytic Epstein-Barr virus replication strategies</title>
		<author>
			<persName><forename type="first">T</forename><surname>Tsurumi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fujita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kudoh</surname></persName>
		</author>
		<idno type="DOI">10.1002/rmv.441</idno>
		<idno type="PMID">15386591</idno>
		<ptr target="https://doi.org/10.1002/rmv.441" />
	</analytic>
	<monogr>
		<title level="j">Rev Med Virol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="3" to="15" />
			<date type="published" when="2004-09-24">2005. 2004/09/24</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Puchhammer-Sto ¨ckl E. Characterization of Epstein-Barr virus Type I variants based on linked polymorphism among EBNA3A, -3B, and -3C genes</title>
		<author>
			<persName><forename type="first">I</forename><surname>Go ¨rzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hgm</forename><surname>Niesters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Cornelissen</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.virusres.2005.11.020</idno>
		<idno type="PMID">16406167</idno>
		<ptr target="http://dx.doi.org/10.1016/j.virusres.2005.11.020.https://doi.org/10.1016/j.virusres.2005.11.020" />
	</analytic>
	<monogr>
		<title level="j">Virus Research</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="issue">1-2</biblScope>
			<biblScope unit="page" from="105" to="114" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Differential gene regulation by Epstein-Barr virus type 1 and type 2 EBNA2</title>
		<author>
			<persName><forename type="first">W</forename><surname>Lucchesi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Brady</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Dittrich-Breiholz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kracht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Russ</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Farrell</surname></persName>
		</author>
		<idno type="DOI">10.1128/JVI.00223-08</idno>
		<idno type="PMID">18480445</idno>
		<idno>PMCID: PMCPmc2493322</idno>
		<ptr target="https://doi.org/10.1128/JVI.00223-08" />
	</analytic>
	<monogr>
		<title level="j">Journal of virology</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="7456" to="7466" />
			<date type="published" when="2008-05-16">2008. 2008/05/ 16</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Carruthers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Ja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Meirleir</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Chronic Fatigue Syndr</title>
		<imprint>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="7" to="116" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Identification of group-common linear epitopes in structural and nonstructural proteins of enteroviruses by using synthetic peptides</title>
		<author>
			<persName><forename type="first">J</forename><surname>Cello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Samuelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Stalhandske</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Svennerholm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jeansson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Forsgren</surname></persName>
		</author>
		<idno type="PMID">7681848</idno>
		<idno type="PMCID">PMC263586</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of clinical microbiology</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="911" to="916" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">High-Throughput Microarray Incubations Using Multi-Well Chambers</title>
		<author>
			<persName><forename type="first">J</forename><surname>Zerweck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Reimer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jansong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Pawlowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tersch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Eckey</surname></persName>
		</author>
		<idno type="DOI">10.1007/978-1-4939-3037-1_2</idno>
		<idno type="PMID">26490464</idno>
		<ptr target="https://doi.org/10.1007/978-1-4939-3037-1_2" />
	</analytic>
	<monogr>
		<title level="j">Methods in molecular biology</title>
		<imprint>
			<biblScope unit="volume">1352</biblScope>
			<biblScope unit="page" from="19" to="26" />
			<date type="published" when="2015">2016. 2015/ 10/23</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome</title>
		<author>
			<persName><forename type="first">O</forename><surname>Fluge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Mella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Bruland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Risa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Dyrstad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Alme</surname></persName>
		</author>
		<idno type="DOI">10.1172/jci.insight.89376</idno>
		<idno type="PMID">28018972</idno>
		<idno type="PMCID">PMC5161229</idno>
		<ptr target="https://doi.org/10.1172/jci.insight.89376" />
	</analytic>
	<monogr>
		<title level="j">JCI insight</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">21</biblScope>
			<biblScope unit="page">e89376</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Index markers of chronic fatigue syndrome with dysfunction of TCA and urea cycles</title>
		<author>
			<persName><forename type="first">E</forename><surname>Yamano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sugimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hirayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kume</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yamato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Jin</surname></persName>
		</author>
		<idno type="DOI">10.1038/srep34990</idno>
		<idno type="PMID">27725700</idno>
		<idno type="PMCID">PMC5057083</idno>
		<ptr target="https://doi.org/10.1038/srep34990" />
	</analytic>
	<monogr>
		<title level="j">Scientific reports</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">34990</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS</title>
		<author>
			<persName><forename type="first">R</forename><surname>Zivadinov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Cerza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hagemeier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Carl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Badgett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Ramasamy</surname></persName>
		</author>
		<idno type="DOI">10.1212/NXI.0000000000000190</idno>
		<idno type="PMID">26770996</idno>
		<idno>PMCID: PMCPmc4708926</idno>
		<ptr target="https://doi.org/10.1212/NXI.0000000000000190" />
	</analytic>
	<monogr>
		<title level="j">Neurol Neuroimmunol Neuroinflamm</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">1</biblScope>
			<date type="published" when="2016-01-16">2016. 2016/01/16</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Epstein-Barr virus antibodies mark systemic lupus erythematosus and scleroderma patients negative for anti-DNA</title>
		<author>
			<persName><forename type="first">I</forename><surname>Fattal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Shental</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Molad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gabrielli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pokroy-Shapira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Oren</surname></persName>
		</author>
		<idno type="DOI">10.1111/imm.12200</idno>
		<idno type="PMID">24164500</idno>
		<idno>PMCID: PMCPmc3904248</idno>
		<ptr target="https://doi.org/10.1111/imm.12200" />
	</analytic>
	<monogr>
		<title level="j">Immunology</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="276" to="285" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">High anti-EBNA-1 IgG levels are associated with earlyonset myasthenia gravis</title>
		<author>
			<persName><forename type="first">D</forename><surname>Csuka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Banati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rozsa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Fust</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Illes</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1468-1331.2011.03636.x</idno>
		<idno type="PMID">22221650</idno>
		<ptr target="https://doi.org/10.1111/j.1468-1331.2011.03636.x" />
	</analytic>
	<monogr>
		<title level="j">Eur J Neurol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="842" to="846" />
			<date type="published" when="2012-01-10">2012. 2012/01/10</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Serologic response to Epstein-Barr virus antigens in patients with systemic lupus erythematosus: a controlled study</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Esen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Yilmaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Uzun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ozdamar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Aksozek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kamali</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00296-010-1573-4</idno>
		<idno type="PMID">20661740</idno>
		<ptr target="https://doi.org/10.1007/s00296-010-1573-4" />
	</analytic>
	<monogr>
		<title level="j">Rheumatol Int</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="79" to="83" />
			<date type="published" when="2010-07-28">2012. 2010/07/28</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Castellazzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tamborino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Negri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Baldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Seraceni</surname></persName>
		</author>
		<idno type="DOI">10.1177/1352458510368051</idno>
		<idno type="PMID">20483883</idno>
		<ptr target="https://doi.org/10.1177/1352458510368051" />
	</analytic>
	<monogr>
		<title level="j">Mult Scler</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="883" to="887" />
			<date type="published" when="2010-05-21">2010. 2010/05/21</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects</title>
		<author>
			<persName><forename type="first">J</forename><surname>Fachiroh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Schouten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hariwiyanto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Paramita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Harijadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Haryana</surname></persName>
		</author>
		<idno type="DOI">10.1086/421245</idno>
		<idno type="PMID">15195243</idno>
		<ptr target="https://doi.org/10.1086/421245" />
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">190</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="53" to="62" />
			<date type="published" when="2004-06-15">2004. 2004/06/15</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">A possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLF-1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">T</forename><surname>Yip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Ngan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Lau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">F</forename><surname>Poon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Joab</forename><forename type="middle">I</forename><surname>Cochet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
		<idno type="PMID">7922994</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="2414" to="2424" />
			<date type="published" when="1994">1994. 1994/11/01</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">A repetitive sequence of Epstein-Barr virus nuclear antigen 6 comprises overlapping T cell epitopes which induce HLA-DRrestricted CD4(+) T lymphocytes</title>
		<author>
			<persName><forename type="first">E</forename><surname>Rajnavolgyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Nagy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Thuresson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Dosztanyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Simon</surname></persName>
		</author>
		<idno type="PMID">10700463</idno>
	</analytic>
	<monogr>
		<title level="j">Int Immunol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="281" to="293" />
			<date type="published" when="2000-03-04">2000. 2000/03/04</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Epstein-Barr virus early antigen diffuse (EBV-EA/D)-directed immunoglobulin A antibodies in systemic lupus erythematosus patients</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Draborg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Jorgensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Nielsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jacobsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">V</forename><surname>Iversen</surname></persName>
		</author>
		<idno type="DOI">10.3109/03009742.2012.665944</idno>
		<idno type="PMID">22646970</idno>
		<ptr target="https://doi.org/10.3109/03009742.2012.665944" />
	</analytic>
	<monogr>
		<title level="j">Scand J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="280" to="289" />
			<date type="published" when="2012-06-01">2012. 2012/06/01</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Exhausted cytotoxic control of Epstein-Barr virus in human lupus</title>
		<author>
			<persName><forename type="first">M</forename><surname>Larsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sauce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Deback</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Arnaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mathian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Miyara</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.ppat.1002328</idno>
		<idno type="PMID">22028659</idno>
		<idno>PMCID: PMCPmc3197610</idno>
		<ptr target="https://doi.org/10.1371/journal.ppat.1002328" />
	</analytic>
	<monogr>
		<title level="j">PLoS Pathog</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">10</biblScope>
			<date type="published" when="2011">2011. 2011/10/27</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Mcclain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">D</forename><surname>Heinlen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Dennis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Roebuck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Harley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>James</surname></persName>
		</author>
		<idno type="DOI">10.1038/nm1167</idno>
		<idno type="PMID">15619631</idno>
		<ptr target="https://doi.org/10.1038/nm1167" />
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="85" to="89" />
			<date type="published" when="2004-12-28">2005. 2004/12/ 28</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Lactoperoxidase-induced protein oxidation in milk</title>
		<author>
			<persName><forename type="first">H</forename><surname>Ostdal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Bjerrum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Pedersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Andersen</surname></persName>
		</author>
		<idno type="PMID">10995295</idno>
	</analytic>
	<monogr>
		<title level="j">J Agric Food Chem</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="3939" to="3944" />
			<date type="published" when="2000-09-20">2000. 2000/09/20</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Disorder in milk proteins: structure, functional disorder, and biocidal potentials of lactoperoxidase</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Almehdar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>El-Fakharany</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">N</forename><surname>Uversky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Redwan</surname></persName>
		</author>
		<idno type="PMID">25772156</idno>
	</analytic>
	<monogr>
		<title level="j">Curr Protein Pept Sci</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="352" to="365" />
			<date type="published" when="2015-03-17">2015. 2015/03/17</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Lactoperoxidase, peroxide, thiocyanate antimicrobial system: correlation of sulfhydryl oxidation with antimicrobial action</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Aune</surname></persName>
		</author>
		<idno type="PMID">352945</idno>
		<idno>PMCID: PMCPmc421877</idno>
	</analytic>
	<monogr>
		<title level="j">Infect Immun</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="456" to="463" />
			<date type="published" when="1978-05-01">1978. 1978/05/01</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<monogr>
		<title level="m" type="main">Antibodies to beta adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. Brain, behavior, and immunity</title>
		<author>
			<persName><forename type="first">M</forename><surname>Loebel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Grabowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Heidecke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Hanitsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wittke</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.bbi.2015.09.013</idno>
		<idno type="PMID">26399744</idno>
		<ptr target="https://doi.org/10.1016/j.bbi.2015.09.013" />
		<imprint>
			<date type="published" when="2016">2016</date>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="32" to="39" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Analysis of Epstein-Barr virus strains and variants in classical Hodgkin&apos;s lymphoma by laser microdissection</title>
		<author>
			<persName><forename type="first">M</forename><surname>Garcia-Cosio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Santon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Reguero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cristobal</forename><forename type="middle">E</forename><surname>Bellas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
		<idno type="DOI">10.14670/HH-23.209</idno>
		<idno type="PMID">17999377</idno>
		<ptr target="https://doi.org/10.14670/HH-23.209" />
	</analytic>
	<monogr>
		<title level="j">Histol Histopathol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="209" to="217" />
			<date type="published" when="2007">2008. 2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Epstein-Barr virus (EBV) genotypes among human immunodeficiency virus (HIV)-related B-cell lymphomas and B-cell post-transplant lymphoproliferative disorders (B-PTLD)-late-onset lymphomas, especially in the HIV setting, are associated with type-B-EBV</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Ibrahim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">P</forename><surname>Menasce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pomplun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Burke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bower</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">N</forename><surname>Naresh</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1600-0609.2010.01460.x</idno>
		<idno type="PMID">20408873</idno>
		<ptr target="https://doi.org/10.1111/j.1600-0609.2010.01460.x" />
	</analytic>
	<monogr>
		<title level="j">Eur J Haematol</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="227" to="230" />
			<date type="published" when="2010-04-23">2010. 2010/04/23</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Epstein-Barr virus can establish infection in the absence of a classical memory B-cell population</title>
		<author>
			<persName><forename type="first">M</forename><surname>Conacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Callard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mcaulay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Chapel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Webster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kumararatne</surname></persName>
		</author>
		<idno type="DOI">10.1128/JVI.79.17.11128-11134.2005</idno>
		<idno type="PMID">16103163</idno>
		<idno>PMCID: PMCPmc1193576</idno>
		<ptr target="https://doi.org/10.1128/JVI.79.17.11128-11134" />
	</analytic>
	<monogr>
		<title level="j">J Virol</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="11128" to="11134" />
			<date type="published" when="2005-08-17">2005. 2005/08/17. 2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<monogr>
		<title level="m" type="main">Epstein-Barr Virus: Pathogenesis and Host Immune Response Springer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Hudnall</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2014">2014</date>
			<biblScope unit="volume">2</biblScope>
		</imprint>
	</monogr>
	<note>Viruses and Human Cancer</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
